Dosage Schedule Study of Pemetrexed Monochemotherapy for Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Status:
Completed
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
Patients affected by non-small cell lung cancer (NSCLC) will be treated in pemetrexed
monochemotherapy regimen for a maximum of 8 cycles. Pemetrexed is an enhancer of some
biomolecules involved in the gemcitabine mechanism of action. Purpose of the trial is to
monitor the blood values of these biomolecules at different time intervals, to optimize the
synergism between pemetrexed and gemcitabine.